Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.

about

Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.

P2860

Q38199707-A71AB3BF-9BB1-461B-88DA-B18C55BECA08 Q40490106-43D2271A-35A4-4913-B7EC-AB3F1E8E9D5F Q50690379-97D52AC0-4166-4E17-AA70-1705E569C6B6

P2860

Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.

Item

http://www.wikidata.org/entity/Q44736591

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Cost-effectiveness of hematopo ...... myeloma and lymphoma patients.

@en

Cost-effectiveness of hematopo ...... myeloma and lymphoma patients.

@nl

type

Item

label

Cost-effectiveness of hematopo ...... myeloma and lymphoma patients.

@en

Cost-effectiveness of hematopo ...... myeloma and lymphoma patients.

@nl

prefLabel

Cost-effectiveness of hematopo ...... myeloma and lymphoma patients.

@en

Cost-effectiveness of hematopo ...... myeloma and lymphoma patients.

@nl

P1476

Cost-effectiveness of hematopo ...... myeloma and lymphoma patients

@en

P2093

Aleš Tichopád

http://www.w3.org/2001/XMLSchema#string

Daniel Lysák

http://www.w3.org/2001/XMLSchema#string

Veronika Vítová

http://www.w3.org/2001/XMLSchema#string

P2860

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Decision trees: an overview and their use in medicine.

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Advances in mobilization for the optimization of autologous stem cell transplantation.

Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.

The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.

What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?

P304

395-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCA.21290

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zdeněk Korístek

P577

2013-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23922227

http://www.w3.org/2001/XMLSchema#string

Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.

about

P2860

P2860

Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698